Clinical stage biotech Affimed N.V. said Wednesday it is terminating its phase I program for AFM11 to focus on its innate immunity portfolio. The company had...
Affimed to end cancer program and focus on innate immunity portfolio, shares slide about 10% - MarketWatch
Words
0
Reading
0 min
Listen
Play
2019-05-22 13:55